

References

HMK R-9

1. Chierichetti F. (2012). 18F-FDG-PET/CT. *Quarterly Journal of Nuclear Medicine and Molecular Imaging*,138-150.
2. Ferro, R., Agarwal, A., Martin-Macintosh, EL., Peller, PJ., Subramaniam, RM. (2015, Mar-Apr) MR imaging and PET/CT in diagnosis and management of multiple myeloma. *Radiological Society of North America*,35(2),438-454.
3. Choi, ES., HA, SG., Kim, HS., HA, JA., et al. (2013 April).Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma. *European Journal of Nuclear Medicine Molecular Imaging*, 40:1836-1842.
4. ACR-SPR Practice Parameter for Performing FDG-PET/CT in Oncology. *American College of Radiology*. 2014.
5. Blue Cross and Blue Shield Association. Oncologic Applications of PET Scanning.Medical Policy Reference Manual. 6.01.26. February/2015.
6. Faasse. T. (2013). Positron Emission Tomography-Computed Tomography Data Acquisition and Image Management. INTECH.
7. Sharma, P., Khangembam, BC., Suman, KCS. et al. (2013) Diagnostic accuracy of 18F-FDG PET/CT for detecting recurrence in patients with primary skeletal Ewing sarcoma. *European Journal Nucl Med Mol Imaging*, 40, 1036–1043.
8. Bodet-Milin, C., Eugene, T., Gastinne, T., Frampas, E., Le Gouill, S., Kraeber-Bodere, F. (2012). FDG-PET in Follicular Lymphoma Management. *Journal of Oncology*. Article ID 370272.
9. F-fluorodexoxyglucose (FDG) PET and PET/CT Practice Guidelines in Oncology. PET Professional Resource and Outreach Source. April 2013.
10. Agrawai A, Rangarajan V. Appropriateness Criteria of FDG PET/CT in Oncology. *Indian Journal of Radiology and Imaging*. 2015 Apr;25(2):88-101.